CoChat

Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights

Turetschek, Karl, Preda, Anda, Novikov, Viktor, Brasch, Robert C., Weinmann, Hanns J., Wunderbaldinger, Patrick, Roberts, Timothy P.L. · 2004 · Journal of Magnetic Resonance Imaging
Cited by 115

The DOI matches its Crossref record.

Abstract

Purpose: To test magnetic resonance (MR) contrast media of different molecular weights (MWs) for their potential to characterize noninvasively microvascular changes in an experimental tumor treatment model. Materials and Methods: MD‐MBA‐435, a poorly differentiated human breast cancer cell line, was implanted into 31 female homozygous athymic rats. Animals were assigned randomly to a control (saline) or drug treatment (monoclonal antibody vascular endothelial growth factor (Mab‐VEGF) antibody) group. In both groups, dynamic MR imaging (MRI) was performed in each animal using up to three different contrast media on sequential days at baseline and follow‐up examination. The MWs of the contrast media used ranged from 557 Da to 92 kDa. Using a bidirectional kinetic model, tumor microvessel characteristics, including the fractional plasma volume (fPV) and transendothelial permeability (K PS), were estimated for each contrast medium. These microvascular characteristics were compared between drug and control groups and between contrast media of different MWs. Results: Tumors grew significantly slower (P < 0.0005) in the drug treatment group than in the control group. Mean K PS and fPV values decreased significantly (P < 0.05) in the Mab‐VEGF antibody‐treated group compared to baseline values using intermediate or macromolecular contrast media (MMCM), but did not change significantly using small molecular contrast media (SMCM). In the control groups, mean K PS and mean fPV values did not reach statistical significance for any of the contrast media used. Conclusion: Therapeutic effects of a Mab‐VEGF antibody on tumor microvessel characteristics can be monitored by dynamic MRI. Intermediate‐size agents, such as Gadomer‐17, offer a substantial dynamic range and are less limited by imaging precision and therefore should be considered a practical alternative to monitor antiangiogenesis treatment effects in a clinical setting. J. Magn. Reson. Imaging 2004;20:138–144. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jmri.20049

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Turetschek, K., Preda, A., Novikov, V., Brasch, R. C., Weinmann, H. J., Wunderbaldinger, P., & Roberts, T. P. L.
Venue
Journal of Magnetic Resonance Imaging
Publisher
Wiley
Published
2004-06-21
Volume
20
Issue
1
Pages
138-144
ISSN
  • 1053-1807 (ISSN-L)
  • 1522-2586
OpenAlex
W2093100973
Cited by
115
References
0
FWCI
10.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.